NEW JERSEY REFORMS
Appeal Bond Reform: SB
2738 (2003). Limits the amount a signatory to
the Master Settlement Agreement can be required to pay to secure the right to
appeal to $50 million.
Collateral Source Rule
Reform: SB 2703, SB 2708 (1987): N.J. Stat. Ann. § 2A:15-92. Provides for awards to be offset
by collateral source payments other than workers’ compensation and life
insurance benefits.
Frivolous Lawsuit Sanction: AB 1366 (1988). Allows a court to assess costs and attorneys’ fees
upon a finding that a complaint, counterclaim, cross-claim or defense of a nonprevailing party was frivolous.
Joint and Several
Liability Reform: SB 1494 (1995). Bars application of the rule of joint and several liability in the recovery of all damages from defendants
found to be less than 60% at fault. (The
law formerly extended the 60% threshold for noneconomic damages only.) The reform does not apply to toxic
torts.
Joint and Several
Liability Reform: SB 2703, SB 2708 (1987): N.J. Stat. Ann. § 2A:15-5.3. Bars application of the rule of joint and several liability in the recovery of all damages from defendants
found to be less than 20% at fault. Bars
application of the rule of joint and several liability
in the recovery of noneconomic damages from defendants found to be between 20%
and 60% at fault.
Medical Liability Reform: Contingent Fee Reform:
N.J. Ct. R. § 1:21-7. Limits
contingent fees in medical liability cases pursuant to a sliding scale provided
in the New Jersey Court Rules.
Product Liability Reform: SB 1495
(1995). Excludes product sellers from strict
liability in product liability actions.
Product Liability Reform: SB 2805
(1987). Provides that a manufacturer or seller
of a product is liable only if the plaintiff proves by a preponderance of the
evidence that the product was not suitable or safe because it: (1) deviated
from the design specifications or performance standards; (2) failed to contain
adequate warnings; or (3) was designed in a defective manner. Provides that a manufacturer or seller is not
liable if at the time the product left the manufacturer’s control there was not
available a practical and feasible alternative design that would have
prevented the harm. Provides
that a product’s design is not defective if the harm results from an inherent
characteristic of the product that is known to the ordinary person who uses or
consumes it. Provides
that a manufacturer or seller is not liable for a design defect if the harm
results from an unavoidably unsafe aspect of a product and the product
was accompanied by an adequate warning. Provides that the state of
the art provision does not apply if the court makes all of the following
determinations: (1) that the product is egregiously unsafe; (2) that the user
could not be expected to have knowledge of the product’s risk; and (3) that the
product has little or no usefulness.
Provides that a manufacturer or seller in a warning‑defect
case is not liable if an adequate warning is given. (An adequate warning is one that a reasonably
prudent person in the similar circumstances would have provided.) Establishes a rebuttable
presumption that a government (FDA) warning is adequate.
Punitive
Damages Reform: Damages Limits: SB 1496 (1995): N.J. Stat. Ann. § 2A:15‑5.14.
Limits the award of punitive damages to the greater of five times
the award of compensatory damages or $350,000.
The reform does not apply to cases involving bias crimes,
discrimination, AIDS testing disclosure, sexual abuse, and injuries caused by
drunk drivers.
Punitive
Damages Reform: Actual Malice: SB 2805 (1987).
Requires a
plaintiff to show that a defendant acted with “actual malice” or “wanton and willful
disregard” for the rights of others. Requires the determination of awards for punitive damages to be
made in a separate proceeding. Provides for an FDA government standards defense to punitive
damages. The reform does not
apply to cases involving environmental torts.
Punitive Damages Reform: Clear and Convincing
Evidence: N.J. Stat. Ann. § 2A:15-5.12.
Requires
a plaintiff to prove punitive damages by “clear and convincing evidence.”